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Objectives: A recent Premier study reported that despite hemostat use, uncon-
trolled bleeding is prevalent across surgery types (32%-68%).  Drawbacks of current 
hemostats include limitations with efficacy on first attempt and sub-optimal ease-
of-use; thus, better hemostats are needed.  A study was conducted to estimate the 
cost impact of a novel fibrin sealant patch (EVARREST™) versus standard of care 
(SoC) in soft tissue and hepatic surgical bleeding. MethOds: An economic model 
quantified 30-day cost impact of EVARREST from a U.S. hospital perspective.  Key 
resources, from four trials, included quantity of initial treatment, re-treatment, 
operating time, hospitalization, transfusion risk, amount transfused, and ventilator 
utilization.  SoC was composed of Surgicel (88% to 100% in soft tissue, 34% to 65% 
in hepatic tissue) and conventional methods (e.g., manual compression, thrombin). 
Transplant patients were excluded from analyses.  The surgical analysis included 
resources clinically related to the significant hemostasis benefit of EVARREST vs. 
control (i.e., initial and re-treatment, operating time, transfusion). A hospital analy-
sis included all resources collected. Published data on U.S. costs were applied to 
resource use. Sensitivity analyses were conducted on several variables including 
number of EVARREST products used. Results: The surgical base-case analysis 
predicted that EVARREST was cost saving vs. SoC by $59 per patient (sensitivity 
range: -$300 to $900).  The hospital analysis predicts further resource reduction 
with EVARREST with cost-savings of $2,789 per patient (sensitivity range: -$1,830 to 
-$3,338).  Results were most sensitive to the number of pads used.  Composite results 
were primarily driven by the large benefit achieved with EVARREST in severe soft-
tissue bleeding. cOnclusiOns: In problematic soft tissue and hepatic bleeding, 
EVARREST may result in important cost savings for hospitals, in addition to meeting 
an important unmet need. This analysis suggests EVARREST’s impact on hospital 
cost may depend on surgical bleeding type and number of pads used. Further study 
in additional populations may confirm findings.
PMD78
EconoMic iMPact of using HarMonic scalPEl tEcHnology in surgEry
Hsiao C., Clymer J.W., Cheng H.
Ethicon Inc., Cincinnati, OH, USA
Objectives: The Harmonic® scalpel has demonstrated clinical and surgical ben-
efits as an effective and efficient alternative to traditional electrosurgery. However, 
ultrasonic devices incur higher device cost than electrosurgery. The aim of this study 
is to review the economic evidence comparing total procedural costs performed 
with ultrasonic devices to conventional techniques. MethOds: A comprehensive 
literature review was conducted to identify publications where ultrasonic energy 
devices were used in comparison with conventional surgical techniques for the 
period 2004-2014. No restriction on the surgical specialty was applied. Primary inclu-
sion criteria were: 1) randomized-controlled studies; 2) human studies; 3) total 
procedure cost was evaluated for economic impact. Articles were reviewed to collect 
direct and indirect cost information such as OR time, blood loss, hospital length of 
stay, resource and surgical consumables, as well as quality of life data. Results: For 
39 articles identified for full-text screening, 9 articles were evaluated based on the 
inclusion criteria. Therapeutic areas included breast, colon, and thyroid surgery. All 
economic studies considered total medical direct costs. Except for one article that 
showed ultrasonic devices to be more expensive and one that showed no economic 
difference, all other articles demonstrated that the higher cost of the Harmonic® 
device is offset by improved clinical outcomes and efficiency without an increase in 
surgical complications, especially in complicated procedures entailing considerable 
loss of blood or longer operative time. The average overall cost savings ranged from 
$85 to $400 USD per patient. Two studies estimated the incremental cost-effective 
ratio and both indicated the Harmonic® device to be superior compared to conven-
tional technique. cOnclusiOns: Ultrasonic devices shorten OR time and improve 
clinical outcomes in a variety of procedures investigated without an increase in 
complications, and thus can be considered as a cost effective alternative to con-
ventional surgical techniques.
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Objectives: Surgical bleeding remains prevalent and associated with substan-
tial burden. Such bleeding can be more difficult to manage in certain surgeries 
(e.g., liver). Hemostats with a fibrinogen, thrombin and patch component may be 
especially beneficial for problematic bleeding types; however, direct comparative 
data are limited. This study indirectly compared the hemostats EVARREST and 
TachoSil. MethOds: A structured literature search identified studies of fibrin 
sealants combined with use of a pad, patch, fleece or sponge, for surgical bleeding. 
The search was restricted to RCTs, 2000 onward, studies including standard of care 
(SoC) and time to hemostasis (TTH). EVARREST (4 trials) and TachoSil (6 trials) were 
identified as the comparators. Pair-wise meta-analyses were completed using a 
random-effects model for hemostat vs. SoC. An adjusted indirect comparison was 
conducted using Bucher methodology and ITC software (Wells, 2009) for calculat-
ing the mean difference (MD) in TTH between EVARREST and TachoSil with 95% 
confidence intervals (CI). Mean TTH was analysed as it is a well-accepted, recom-
mended measure. Typically, TTH measurements began at either 3 or 4 minutes. 
SoC was used as the ‘anchor’ to perform the indirect comparison and consisted 
of either conventional methods or topical hemostats. Indirect comparisons were 
completed for all surgery types and a liver surgery subgroup. Results: A total of 
894 patients were assessed. Across surgery types, the adjusted indirect comparison 
demonstrated EVARREST reduced mean TTH by 1.15 minutes compared to TachoSil 
(MD: -1.15; 95%CI: -3.29, 0.99), however, this difference was not statistically sig-
nificant. In the subgroup of liver surgical bleeding, EVARREST significantly reduced 
mean TTH by 2.73 minutes (MD: -2.73; 95%CI: -4.48, -0.981). cOnclusiOns: This 
analysis suggests EVARREST may provide better hemostasis than TachoSil, particu-
equipment costs ($495 list price of Revolve per use) and depreciated cost of centrifu-
gation ($10 per use). Annualized difference in costs was also estimated. Results: 
Base case assumed 100 AFGs per year (150mL of fat injected per case). Mean time to 
complete AFG was substantially faster using Revolve than centrifugation: 29.1 min-
utes versus 116.1 minutes (range: 25.1-32.0 versus 104.1-125.8 minutes, respectively). 
Mean volume of fat injected was greater for Revolve than centrifugation: 210.0mL 
versus 92.0mL (ranges: 179.0-241.2 versus 82.4-101.2mL, respectively). Consequently, 
rate of completing AFG was greater with Revolve than centrifugation: 5.2mL/min 
versus 1.3mL/min (range: 4.7-6.0 versus 1.2-1.4mL/min, respectively). Estimated 
cost savings for Revolve versus centrifugation was $2,075 per case and $207,476 per 
year. cOnclusiOns: As popularity of AFG increases, evaluating economic impact of 
AFG systems becomes essential. Based on current findings, Revolve system results in 
substantial OR time and cost savings compared to centrifugation.
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intEgrating Big Data to assEss tHE EconoMic iMPact of tHE 
iMPlantaBlE carDiovErtEr DEfiBrillator tHEraPy
Madotto F., Conti S., Chiodini V., Mantovani L.G., Fornari C., Cesana G.
University of Milano - Bicocca, Monza, Italy
Objectives: The main purpose of this study was to link clinical and administra-
tive healthcare databases in order to assess the economic impact of implantable 
cardioverter defibrillator (ICD) with or without cardiac resynchronization pacing 
(CRT-D) in Lombardy, the most populated Italian region providing universal health-
care coverage for about 10 million inhabitants. MethOds: Data were extracted 
from: i) data warehouse DENALI, that organizes healthcare administrative databases 
concerning all subjects covered by Lombardy Health System (HS); ii) national ICD 
database. After linking DENALI and clinical information extracted from the ICD 
database, we identified patients with ICD and followed them from the date of the 
first implant to 12/31/2010, recording hospitalizations, drugs and outpatient claims. 
Direct healthcare costs were analysed from the perspective of the HS. We estimated 
mean annual per-capita costs after the first ICD implant: overall and stratified by 
indication (primary and secondary prevention) or type of implanted device (sin-
gle-chamber, dual-chamber and CRT-D). Results: During the period 2003-2010, 
12,525 subjects underwent a first ICD implant. Mean annual per-capita cost during 
follow-up was € 6,086 (95%CI: 5,970-6,211): 72.7% due to hospitalizations (€ 4,422), 
15.7% to pharmacological therapies (€ 957) and 11.6% to outpatient services (€ 706). 
No difference was observed between the mean annual expenditure for primary 
(€ 6,179; 95%CI: 6,001-6,353) and secondary (€ 5,996; 95%CI: 5,821-6,185) prevention. 
As for the type of implanted device, patients with CRT-D cost more than those with 
single-chamber or dual-chamber: respectively € 6,592 (95%CI: 6,376-6,847), € 5,728 
(95%CI: 5,541-5,972) and € 5,932(95%CI: 5,717-6,117). The difference was attributable 
to hospitalization expenses. cOnclusiOns: ICD use is growing and it is important 
to assess the efficacy and the burden of this therapy, given its economic implica-
tions. The combined use of clinical information from national ICD database and big 
administrative data could overcome the limitation of both data sources, leading to 
an improvement in the monitoring of ICD therapy.
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Objectives: Diabetes (DM) is rapidly growing in China, affecting > 114 million peo-
ple. Lipohypertrophy (LH) is a known, preventable complication amongst insulin-
injecting DM patients. This study demonstrates the economic and patient burden of 
LH in China. MethOds: An observational study was conducted among 401 insulin-
injecting adult patients with DM from 4 cities, 2 with and 2 without pen needle 
reimbursement (PNR). Demographics, medical history, direct and indirect costs, 
insurance and PNR status were collected via patient survey, followed by HbA1c tests 
and physical exam to assess LH. Results: LH was present in 52.9% of participants. 
Patients were an average of 59.6 (SD= 11.5) years old and took insulin 5.6 (SD= 4.6) 
years, averaging 33.0 (SD= 18.4) U/day. HbA1c was 8.2% (1.8) and 7.7% (1.5), respec-
tively, in those with and without LH (p= 0.003). LH was associated with higher daily 
insulin dose (38.1U vs 27.1U, p< 0.001) and cost (RMB 8.2 vs 5.8, p< 0.001). Those with 
LH averaged 2.3 (2.2) nodes, had higher frequency of PN reuse (median 13.0 vs 7.5, 
p= 0.003), and greater total 6-month direct costs (RMB 5506.9 vs 5258.0, p= 0.037). 
With 8.4 million insulin injectors in China, the estimated excess annual direct cost 
of LH is RMB 2.2 billion ($360 million). Average pain scores (0-10) were higher if LH 
was present (2.7 vs. 2.0, p= 0.021), if ≥ 3 nodes were present (3.8 vs. 2.3, p< 0.001), and if 
PNs were not reimbursed (2.8 vs. 1.7, p< 0.001). Patient satisfaction decreased as pres-
ence, number, and size of LH nodes increased (all p< 0.05). cOnclusiOns: Adverse 
effects and implications of LH reach over half of insulin-injecting patients in China. 
Assessing for LH and providing patient education on proper injection technique, 
including injection site rotation and reducing PN reuse, should be incorporated into 
routine DM management. Doing so may decrease this preventable complication, 
which may lessen LH-related economic and patient burdens.
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spending using Dartmouth Atlas of Health Care online data. Results: Among the 
155,841 patients, 5.9% had a depression diagnosis within 30 days after AMI admis-
sion. DACC-based ADRs captured considerable variation in depression diagnosis 
(IQR: 0.74 – 1.21) and relatively low and high zip code-level ADRs were dispersed 
across the United States. ADRs for depression diagnosis were statistically signifi-
cantly related to Medicare spending (Pearson correlation coefficient = 0.14, p < 0.01), 
but not local physician supply. cOnclusiOns: Substantial geographic variation 
in depression diagnosis exists across the United States. Areas with higher general 
healthcare spending were more likely to have higher depression diagnosis rates. 
Further research is needed to explore if geographic variation in diagnosis affect 
health and economic outcomes to address whether depression was correctly, over- 
or under-diagnosed.
DisEasE-sPEcific stuDiEs
DiaBEtEs/EnDocrinE DisorDErs – clinical outcomes studies
PDB1
urinary tract infEction aMong tHE sglt 2 inHiBitors:  
a MEta-analysis of 19 ranDoMizED controllED trials
Gangal N.S., Kelton C., Heaton P.C.
University of Cincinnati, Cincinnati, OH, USA
Objectives: The goal of this meta-analysis was to determine if within the 
sodium- glucose cotransporter 2 (SGLT 2) inhibitors class, any individual drug 
increases the risk of urinary tract infection (UTI). MethOds: Data base search 
was conducted using Medline, PubMed, and Google Scholar. Study included trials 
of FDA approved SGLT 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. 
To ensure internal validity of the selected studies, only randomized controlled 
trials which included patients with diabetes were included. Any trials with any 
special groups of patients, for example, patients with cardiovascular disease were 
excluded. Non-randomized trials, case reports, editorials, letters to the editors, 
and studies with no comparison group were excluded. Trials which did not report 
UTI as a side effect were excluded. A meta-analysis was conducted and data was 
pooled using odds ratio and 95% confidence intervals. All analysis was performed 
using SAS version 9.4. Results: When the three drugs were compared, there 
was no significant difference in odds of developing a UTI. Sensitivity analyses 
were performed by excluding, in turn, the contribution of each study to the meta-
analysis data. There was no significant difference in the results. cOnclusiOns: 
Although the study reinforced the finding that urinary tract infection is one of the 
major adverse events caused by this class of antidiabetic drugs, this meta-analysis 
suggested that there was no significant difference in risk of UTIs among the three 
SGLT 2 inhibitors on the market.
PDB2
stuDy of PatiEnt rElatED outcoMEs of tyPE 2 DiaBEtEs anD 
coMParativE analysis of PioglitazonE salEs PrE anD Post Ban in 
MuMBai,inDia
Yande S., Hegde P., Velankar K., Dhumal T., Majumdar A.
Bombay College Of Pharmacy, Mumbai, India
intROductiOn: Diabetes mellitus is the leading disorder in India. 
Thiazolidinediones have been marketed since 1997 and are effective glucose low-
ering drugs, but individual drugs of this category like Pioglitazone have been linked 
to serious side effects like bladder cancer and hence banned in India. Objectives: 
A survey was conducted to evaluate the prescription trends of type II diabetes 
in Mumbai, India and the adverse drug reactions associated with it. To evaluate 
the effect of sales of pioglitazone after its ban was removed. To observe the vari-
ation in prescription trends as compared to normal trends in case of drug resist-
ance. MethOds: Two sets of questionnaires were prepared which captured patient 
demographics, prescription trends and adverse drug reactions of type II diabetes 
patients in Mumbai, India.The questionnaires targeted 75 drug stores, 40 General 
Practitioners and 3 government hospitals. Results: Average number of prescrip-
tions received by the pharmacist under the survey were 30-40 per week. Males are 
more affected than females. The trend of prescriptions prescribed by the general 
practitioners is similar to that of prescriptions received by the drug stores. Metformin 
is majorly prescribed followed by Glimepiride, Voglibose, Pioglitazone. Contrasting 
results were obtained with respect to Pioglitazone on comparing the prescription 
trends of doctors to the pharmacists as it was often prescribed by doctors after its 
ban was removed but its sales had not increased. The most number of adverse reac-
tions were shown by Metformin and Glimepiride followed by Pioglitazone,Gliptins 
and Incretin Mimetics showed minimum side effects. cOnclusiOns: From our 
results it was observed that there was no increase in the sales of Pioglitazone. 
Patients were treated with Metformin and Metformin-Glimepiride combination as 
first line treatment. Pioglitazone and insulin are most commonly prescribed in 
case of a drug resistance. Dose variations were suggested by general practitioners 
in case of a drug resistance.
PDB3
coMParativE outcoMEs of tEstostEronE tHEraPy vErsus no 
trEatMEnt in HyPogonaDic MEn
Noone J., Blanchette C.M., Van Doren B.A., Zacherle E.
University of North Carolina at Charlotte, Charlotte, NC, USA
Objectives: Testosterone therapy for the treatment of hypogonadism in older 
men is controversial. Previous studies on benefits have been inconclusive and 
there is the belief that the known potential for negative cardiac outcomes out-
weighs any benefit. We used a sample of Medicare patients to test the time from 
diagnosis of hypogonadism to positive and negative events related to treating 
hypogonadism MethOds: Using a 5% random sample of Medicare LDS claims 
larly in liver surgical bleeding. Caution must be taken in interpreting results given 
some patient differences. A head-to-head trial comparison may be necessary to 
confirm differences between products.
PMD80
EffEct of HyDroPHilic coating isotonic to urinE on infEctions anD 
coMPlications aMong usErs of intErMittEnt urinary catHEtErs
Neovius K.1, Svensson J.1, Åberg-Håkansson M.2, Lundqvist T.2
1Aux Analysis, Stockholm, Sweden, 2Wellspect HealthCare, Mölndal, Sweden
Objectives: Infections and urethral trauma are common complications among 
patients using intermittent urinary catheters. The objective of this study was to 
investigate the effect on complications of switching to a catheter with hydrophilic 
coating isotonic to urine. MethOds: A questionnaire was sent to 694 individuals 
performing daily intermittent urinary catheterization in Europe and the USA. The 
participants were asked to report infections and complications, as well as cur-
rent and previous catheter type if applicable. Only patients reporting to currently 
be using a catheter type with hydrophilic coating isotonic to urine were included 
in the study. The patients who had previously switched catheters were asked to 
estimate their current infections, complications and problems as much less, less, 
same, more or much more compared to before the switch. Wilcoxon signed rank 
tests were carried out to detect changes in level of consequences after switching. 
Analyses were performed separately for patients who switched but stayed on cath-
eters with hydrophilic coating isotonic to urine and patients who switched from 
another catheter type. Results: The initial response rate was 57% (n= 391) of which 
74% (n= 288) were using catheters with hydrophilic coating isotonic to urine. 129 
patients reported to have switched catheters, 41 (32%) stayed on the same catheter 
type, i.e. hydrophilic coating isotonic to urine, and 88 (68%) switched from another 
catheter type. Among those patients who switched from another catheter type to a 
catheter with hydrophilic coating isotonic to urine, an average of 15% reported more 
and 32% reported less infections (p= 0.042), UTIs (p= 0.041), complications (p= 0.062) 
and general problems (p= 0.001). The corresponding numbers for the patients who 
stayed on catheters with hydrophilic coating isotonic to urine were not statisti-
cally significant. cOnclusiOns: This study indicates that patients performing 
daily intermittent catheterization can benefit from switching to a catheter with 
hydrophilic coating isotonic to urine.
PMD81
is tHErE utility in clinical utility MoDEling for Diagnostic 
tEcHnologiEs?
Hertz D., Taggart C., Waterman J., Armstrong S.
GfK Custom Research, Wayland, MA, USA
Objectives: Demonstrating clinical utility is a challenge for diagnostic companies; 
MolDx denied 40% of CMS applications due to insufficient clinical utility data. Trials 
to prove clinical utility can be expensive and lengthy. Modeling can be a relatively 
inexpensive method in establishing clinical utility for a novel diagnostic. The objec-
tive of this study was to determine the utility of and identify requirements and hur-
dles for developing clinical utility models. MethOds: We conducted a qualitative 
review of 15 clinical utility models for novel diagnostics across diverse therapeutic 
areas and encompassing screening, diagnostic and monitoring tests. Models were 
assessed based on data requirements, validity of outcomes, and ability to secure 
reimbursement. Results: Clinical utility depends on: (1) test performance (rela-
tive to standard of care), (2) physician practice change (confidence in test results), 
(3) patient compliance/behavioral change, (4) availability and proven benefits of 
alternative treatment course, (5) and/or reductions in adverse events. Modeling for 
clinical utility is most effective in areas where clear treatment protocols exist and 
evidence supporting the efficacy of an alternative treatment is robust. Evidence sup-
porting practice change and patient compliance are frequently unknown, but may 
be informed by literature, claims analysis and/or EMR data. Modeling clinical utility 
is most challenging when treatment guidelines are broad and outcomes evidence is 
not well differentiated. cOnclusiOns: Modeling is a logical first step in assessing 
clinical utility. It’s a cost-effective way of identifying a target population and best 
test placement in the continuum of care through comparison of alternative strate-
gies. Additionally, it can be useful in identifying evidence gaps and prioritizing data 
collection. However unless the data supporting the model is strong, it is insufficient 
on its own to secure reimbursement. Analysis of claims and EMR data can be an 
excellent data source for supporting diagnostic utility modeling.
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Objectives: Depression treatment after acute myocardial infarction (AMI) is impor-
tant to improve outcomes. Identification of geographic variation in depression 
diagnosis is a needed first step to understand practice variation and its outcome 
implications. The objective of this study was to assess the extent of geographic 
variation in depression diagnosis of Medicare patients after AMI. MethOds: A ret-
rospective cohort of Medicare beneficiaries hospitalized with AMI during 2007-2008 
(no AMI and depression diagnosis in the previous year) was included. Depression 
diagnosis was identified if a patient had a depression diagnosis within 30 days 
after AMI admission. Using driving-area-for-clinical-care (DACC) method, zip code-
specific area diagnosis ratios (ADRs) were estimated as number of patients receiving 
a depression diagnosis divided by the sum of predicted probabilities of receiving 
a depression diagnosis across patients in a driving-time zip code. Linear regres-
sion yielded predicted probability estimates of each patient receiving a diagnosis 
based on demographics, prior comorbidities/treatments, climate, and neighborhood 
characteristics. Maps were created to contrast geographic variation in depression 
diagnosis based on ADRs. Overall healthcare utilization was measured by Medicare 
